<?xml version="1.0" encoding="UTF-8"?>
<p>Here, we describe the introduction of ZIKV into the Pediatric Dengue Cohort Study (PDCS), a long-standing pediatric dengue cohort established in 2004 in Managua, Nicaragua, in which the DENV immune history of the participants is well-characterized [
 <xref rid="pmed.1002726.ref024" ref-type="bibr">24</xref>â€“
 <xref rid="pmed.1002726.ref026" ref-type="bibr">26</xref>]. The incidence of symptomatic and inapparent ZIKV infections from January 1, 2016, to February 28, 2017, was estimated, together with associated demographic risk factors. The effect of prior DENV infection on ZIKV infection and disease was also analyzed.
</p>
